Project Grant HT94252310394
Award Date
9/1/23
Completion Date
8/31/26
Dollars Obligated
$231K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Australia
Similar Awards
The University of Adelaide in Australia was awarded a $1,005,845 Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420). The grant will fund a research project from September 2022 through September 2025 to exploit prostate cancer metabolic dependencies to develop new therapeutics and circulating prognostic and predictive biomarkers. The Military Medical Research and Development program supports basic, applied, and...
The Department of Defense's Defense Health Agency awarded Duke University a $1,344,946 Project Grant on September 1, 2023 through the Military Medical Research and Development program (CFDA 12.420). This grant supports a 3-year research project titled "Understanding Heterogeneity and Improving the Precision of Prostate Cancer Clinical Outcomes in the Modern Era." The research aims to advance understanding and treatment of prostate cancer, with a focus on improving clinical outcomes for...
This federal Project Grant award in the amount of $1,229,700.00 was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The award is supporting research conducted by the Dana-Farber Cancer Institute, Inc. (DFCI) in Boston, Massachusetts focused on "DISSECTION OF MOLECULAR ASSOCIATIONS OF RESPONSE TO NEOADJUVANT ANTIANDROGEN THERAPIES IN HIGH-RISK LOCALIZED PROSTATE CANCER." The 4-year research project aims to advance the...
This $1,120,707 Project Grant awarded by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) federal grant program supports research on a novel calcium channel inhibitor for the treatment of advanced metastatic prostate cancers resistant to next-generation antiandrogen therapy. The grant was awarded to the University of Queensland in Australia, a leading research university with a proven track record of conducting sophisticated medical and scientific...
The Department of Defense's Defense Health Agency awarded a $1,205,784 Project Grant to Queensland University of Technology (QUT) under the Military Medical Research and Development program (CFDA 12.420). The grant, titled "ACCELERATING TRANSLATION OF A NOVEL METAP2 INHIBITOR IN TREATMENT-RESISTANT AND AGGRESSIVE-VARIANT PROSTATE CANCER," runs from July 1, 2024 to June 30, 2027. The project aims to accelerate the translation of a novel MetAP2 inhibitor therapy for treating...
The Defense Health Agency awarded a $468,000 Project Grant to the University of California, Los Angeles under the Military Medical Research and Development federal grant program (CFDA 12.420) to support research developing new therapeutic strategies to target TROP2 in aggressive prostate cancer. The two-year award beginning March 15, 2023 will fund research efforts to investigate medical solutions for prostate cancer on the battlefield and transform health care for service members and the public...
The U.S. Defense Health Agency awarded a $1,449,000 Project Grant to Duke University to conduct research aimed at "Identifying Essential Molecular Mechanisms for Advanced Prostate Cancer Growth by a New Chemical Compound." This grant is funded under the Department of the Army Medical Command's Military Medical Research and Development program (CFDA 12.420), which supports biomedical research to improve the health and care of military service members, veterans, and their families. The...
The University of Sydney, through its International Clinical Trials Symposium division, was awarded a $3,580,840 Project Grant from the U.S. Department of the Army Medical Command under the Military Medical Research and Development (CFDA 12.420) federal grant program. The grant, titled "HEROIC PROSTATE CANCER PRECISION HEALTH (PCAPH) AFRICA1K: POWERING PRECISION HEALTH TO IMPROVE PROSTATE CANCER OUTCOMES IN AFRICA," will support advanced biomedical research initiatives focused on...
This $738,775 Project Grant was awarded on September 30, 2024 by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) federal grant program. The grant supports the "HEROIC PROSTATE CANCER PRECISION HEALTH (PCAPH) AFRICA1K: POWERING PRECISION HEALTH TO IMPROVE PROSTATE CANCER OUTCOMES IN AFRICA" research project, which will be conducted by the University of Pretoria in South Africa. The project aims to advance precision health approaches for...
This federal Project Grant award in the amount of $1,927,373.00 was provided by the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420). The grant supports research to develop targeted therapies for metastatic prostate cancers classified by subtypes of DNA repair deficiency. The primary awardee is the Fred Hutchinson Cancer Center, a prominent non-profit medical research organization located in Seattle, Washington. The grant has a performance...